Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Involvement of p53 in gemcitabine mediated cytotoxicity and radiosensitivity in breast cancer cell lines.

Gene - 1 May 2012

Salem Sameer D, Abou-Tarboush Faisal M, Saeed Nadeem M, Al-Qadasi Waheeb D, Farah M Abul, Al-Buhairi Muneera, Al-Harbi Najla, Alhazza Ibrahim, Alsbeih Ghazi

Abstract excerpt

Gemcitabine (2',2'-difluoro-2'-deoxycytidine; dFdCyd) is one of the anti-metabolites drugs that target DNA replication. We evaluated dFdCyd cytotoxicity and its radiosensitizing ability in human breast cancer cell lines, MCF-7 (wild-type p53) and MDA-MB-231 (mutant-type p53) along with normal mammary epithelial cell line (MCF-12) for comparison. Radiosensitivity and cytotoxicity were measured by the clonogenic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Cell Cycle

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to DNA Breaks, Double-Stranded

Share to Electrophoresis, Gel, Pulsed-Field

Share to Epithelial Cells

Share to Gemcitabine

Share to Radiation-Sensitizing Agents

Source

Identifiers

PMID: 22353361
DOI: 10.1016/j.gene.2012.01.099

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Involvement of p53 in gemcitabine mediated cytotoxicity and radiosensitivity in breast cancer cell lines.PMID 22353361Read ↗

Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines.Semantic proximity Read ↗

Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.Semantic proximity Read ↗

Role of p53 mutations in the radiosensitivity status of tumor cells.Semantic proximity Read ↗

Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncologySemantic proximity Read ↗

Key points of basic theories and clinical practice in rAd-p53 (Gendicine™) gene therapy for solid malignant tumorsSemantic proximity Read ↗

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.Semantic proximity Read ↗

The dual role of mutant p53 protein in chemosensitivity of human cancers.Semantic proximity Read ↗

Cell proliferation and cell cycle alterations in oesophageal p53-mutated cancer cells treated with cisplatin in combination with photodynamic therapy.Semantic proximity Read ↗

Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell linesSemantic proximity Read ↗

DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatinSemantic proximity Read ↗

The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic.Semantic proximity Read ↗

Apoptosis Induction by 3EE, 20Ac-Ingenol in p53- and K-RAS-Mutated Pancreatic Cancer, Panc-1 Cells Overexpressing Cyclin D1 Through Cdk2/E2F1 and ARF ActivationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.